Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Alkermes CEO Flags Six Clinical Readouts in 12 Months, LUMRYZ Filing Ahead
Alkermes Showcases Research From Psychiatry and Sleep Portfolios at the Neuroscience Education Institute Fall Congress
Alkermes plc (ALKS) Q3 2026 Earnings Call Transcript
What Alkermes (ALKS) Said on Its Q3 Earnings Call
Alkermes (ALKS) Reports Q3 Earnings: What Key Metrics Have to Say
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Alkermes plc Reports Third Quarter 2026 Financial Results
Alkermes (NASDAQ:ALKS) vs. Vericel (NASDAQ:VCEL) Head to Head Contrast
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V.
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Stock Picks From Seeking Alpha's September 2026 New Analysts
Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
Already premium?